Skip to main content
TipRanks
Go Ultimate75% OFF

Brainsway (BRSYF) AI Stock Analysis

8 Followers
BRSYF

Brainsway

(Other OTC:BRSYF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Installed Base and Recurring Revenue VisibilityA growing installed base and substantial remaining performance obligations support revenue visibility beyond individual equipment sales. Multiyear agreements, customer retention and enterprise relationships can deepen recurring revenue, improve utilization economics and make future growth more durable.
Negative Factors
Operating Expense Growth and Modest Operating MarginsHigher sales, research and administrative spending can absorb a meaningful portion of gross-profit gains, particularly while the operating margin remains modest for a high-gross-margin model. Continued investment may support growth, but it creates execution risk if revenue expansion does not outpace the cost base.

Brainsway (BRSYF) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%BRSYF+30.31%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.29B
Dividend Yield
―
Average Volume (3M)
259
Price to Earnings (P/E)
41.2
Beta (1Y)
0.52
Revenue Growth
33.07%
EPS Growth
53.24%
Country
US
Employees
129
Sector
General
Sector Strength
55
Industry
Medical - Specialties

Brainsway Business Overview & Revenue Model

Company Description

Established in Jerusalem, Israel, in 2003, BrainsWay Ltd. specializes globally in creating and distributing advanced, non-invasive neurostimulation therapies designed to address a wide array of mental health and neurological conditions. The company's...

Brainsway Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-10.21%|Next Earnings Date:Mar 17, 2027
Earnings Call SentimentPositive

The call was strongly positive, marked by 34% revenue growth, 44% growth in system shipments, expanding gross and operating margins, higher cash flow, increased reimbursement coverage, strong demand for SWIFT and OCD, and an outlook at the upper end of or potentially modestly above prior guidance. The company also reported preliminary clinical results, pending regulatory work, early-stage home-use commercialization and higher operating expenses, but these issues did not outweigh the reported financial and commercial progress.

Positive Updates

Strong Third-Quarter Revenue and System Shipments
BrainsWay shipped 130 Deep TMS systems during the third quarter, representing 44% year-over-year growth. Revenue increased 34% year-over-year to $18.1 million from $13.5 million, while revenue for the first nine months of 2026 increased 35% to $50.8 million.

Negative Updates

Higher Operating Expenses and Nonrecurring Charges
Third-quarter sales and marketing expenses increased to $5.5 million from $4.7 million, research and development expenses increased to $3.5 million from $2.4 million, and general and administrative expenses increased to $2.5 million from $1.8 million. Total operating expenses rose to $11.5 million from $8.9 million and included approximately $1 million of additional one-time expenses related to share-based compensation and other nonrecurring payments.

Company Guidance

For full year 2026, management expects results to be at the upper end of its previously issued guidance range, with the potential to modestly exceed those ranges; operating income is expected to be in the upper end of guidance. For 2027, management said there is no formal guidance, but expects operating expenses to increase between 15% to 20%, to continue and increase the margin, and cited book-to-bill of around 1.3 -- 1.4x. Management also expects international revenue growth of between 50% or even 100%, expects partnerships to open up between 50, sometimes even more locations in the next 3 years, and said the Alzheimer's feasibility study is expected to be completed by end of 2027, with a potential multicenter clinical trial costing between $3 million to $4 million over 2.5 or 3 years.

Brainsway Risk Analysis

Brainsway disclosed 67 risk factors in its most recent earnings report. Brainsway reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.The price of our ADSs may rely on the research and reports of equity research analystsQ4, 2023
2.We may be unable to manage our anticipated growth effectively, which could make it difficult to execute our business strategy and we may even be unable to forecast our future growth accurately.Q4, 2023

Brainsway Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

BRSYF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IL:SOFWIL:SOFW72OutperformILS 1.27B31.48――25.84%1717.73%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-50%0%50%100%BRSYFIL:ILXIL:ALMDIL:EPITIL:SOFWIL:PLSMDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BRSYF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BRSYFBrainsway 10.432.4330.31%
IL:ILXILEX Medical Ltd.4790.00-1940.10-28.83%
IL:ALMDAllmed Solutions Ltd.30.10-2.00-6.23%
IL:EPITEPITOMEE MEDICAL LTD263.30-463.30-63.76%
IL:SOFWSofwave Medical Ltd.3454.00529.0018.09%
IL:PLSMPulsenmore464.00-2108.49-81.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.